Navigation Links
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
Date:12/23/2009

st deal with potential interactions with other medications. LIVALO offers a new statin option, with LDL lowering consistent with the commonly administered doses of Lipitor® and Zocor®, and significantly greater LDL lowering in the elderly compared to Pravachol®," stated LeRoy LeNarz, M.D., senior medical director at Lilly.

"It is with great pleasure that we partner with an internationally-renowned company like Lilly," said Yoshihiro Miwa, Kowa president and CEO. "With a joint effort by Lilly, Kowa and Kowa Pharmaceuticals America, we hope to pave the way for the efficient market entry and establish a presence with LIVALO in the statin market in the U.S. and Latin America."

"We are excited to partner with Lilly as we work to establish the LIVALO brand and expand Kowa Pharmaceuticals America's presence in the U.S. market," said Ben Stakely, president and CEO of Kowa Pharmaceuticals America.

About LIVALO

LIVALO is a fully synthetic statin originating from Japan. The efficacy of LIVALO has been evaluated against atorvastatin, simvastatin, and pravastatin in patients with primary hyperlipidemia or mixed dyslipidemia. In these studies, LIVALO effectively reduced LDL-C, including in patients with diabetes, the elderly, and patients with 2 or more risk factors for coronary artery disease. Unlike many statins, LIVALO is only minimally metabolized by the liver Cytochrome P450 enzyme system, suggesting that the potential for clinically significant drug interactions between LIVALO and drugs that inhibit or that are metabolized by CYP450 enzymes, including warfarin, would be reduced.

Since its launch in Japan, South Korea, Thailand and China, LIVALO has been successfully used in these countries to treat hypercholesterolemia and familial hypercholesterolemia, and has accumulated millions of patient-years of exposure. In Japan, sales of LIVALO for fiscal year 2008 reached 34 billion yen (approximat
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... 2014  Training market researchers to spot and ... in today,s highly competitive global marketplace. As resources ... effectively and efficiently produce high performing analysts, regardless ... Effective training programs can help these ... internal clients by developing analysts who can drive ...
(Date:10/17/2014)... -- Research and Markets  has announced the ... of China Dialysis Market, 2014-2018" report to ... 2013 version, this update Report provides detailed analysis ... the relevant effect in recent three years, and ... it analyzes Chinese private-owned hemodialysis services. In the ...
(Date:10/17/2014)... BALTIMORE, Md. , Oct. 17, 2014 /PRNewswire-USNewswire/ ... Center for Medical Technology Policy: The ... from the FDA, public and private payers, medical ... representatives, clinicians, and other experts January 12, 2015 ... effectiveness and value of weight loss treatments.  Participants ...
Breaking Medicine Technology:Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2
(Date:10/20/2014)... DALLAS (PRWEB) October 20, 2014 It’s hard ... for many orphans and vulnerable children around the world, it’s ... by some people, many children are forced to walk barefoot ... for their families or play with their friends. , ... partnering with Air1 Radio in October to encourage ...
(Date:10/19/2014)... and Hastings, a Phoenix personal injury law firm with ... area and across Arizona reports record demand in 2014 ... Statistics have indicated a steady increase in automobile accidents ... and Hastings has seen a steady increase in the ... injured through no fault of their own that is ...
(Date:10/19/2014)... October 20, 2014 This report ... Partial Seizure, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ... and press releases. It also reviews key players ... and special features on late-stage and discontinued projects. ...
(Date:10/19/2014)... SweetDressy.com, a professional company of women’s dresses and ... evening dresses . All the company’s old and ... discount is up to 66 percent off. , ... fashion field. Its dress specialists are striving to make ... of the world. All the company’s items are unique, ...
(Date:10/19/2014)... spondylitis is a systemic disease that causes inflammation ... have affected members of the ancient Egyptian royal ... Arthritis & Rheumatology , a journal of the ... finding instead a degenerative spinal condition called diffuse ... from the 18th to early 20th Dynasties. ...
Breaking Medicine News(10 mins):Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Mummy remains refute antiquity of ankylosing spondylitis 2
... , , TULSA, Okla., ... its service area across Oklahoma by partnering with several EMS providers ... 1st, 2009. , , Since the commercial ... 1.3 million people served by the Emergency Medical Services Authority (EMSA) ...
... finds more evidence in areas where more men ... -- High levels of persistent environmental chemicals are ... countries with high rates of male reproductive problems, ... endocrine-disrupting chemicals, or EDCs, are commonly found in ...
... , , EMERYVILLE, Calif., Sept. ... today announced that it will webcast an investor briefing on ... Speakers will review clinical data for Nexavar in breast cancer ... European Society for Medical Oncology (ESMO) Multidisciplinary Congress in Berlin. ...
... , LAKE FOREST, Ill., Sept. 24 ... pharmaceuticals, and Synerx Pharma, LLC, announced today the launch of ... Paladin Labs, Inc. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO ... to Bioniche,s product offering further broadens our base of niche ...
... introduction of statins to treat high cholesterol, the decline ... double that experienced by the poor. While statins ... health, their use may have contributed to expanding social ... research by Virginia W. Chang, MD, PhD, of the ...
... , , NEW ... market research report is available in its catalogue. , ... Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays ... http://www.reportlinker.com/p0119228/H1N1-(Swine-Influenza)-Market-Assessment-(Latest-Data-Company-Profiles-Implications-for-Immunoassays-and-Molecular-Assays).html , , ...
Cached Medicine News:Health News:Oklahoma Medics Embracing iB Web Service 2Health News:Environmental Chemicals May Affect Male Reproduction 2Health News:Bioniche Pharma and Synerx Pharma Launch Fomepizole Injection 2Health News:Reportlinker Adds H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays) Report 2Health News:Reportlinker Adds H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays) Report 3Health News:Reportlinker Adds H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays) Report 4
Incontinence Pessaries...
Incontinence Dish - Stress Incontinence with mild prolapse. Incontinence Dish with support - Stress Incontinence with mild prolapse and mild cystocele...
... is designed for third degree ... as a cystocele and rectocele. ... both with and without drainage ... tie to aid in removal. ...
... Gellhorn Pessary is used for ... prolapse, or procidentia. It has ... and comes in nine sizes. ... easily folds over for insertion, ...
Medicine Products: